A228760 Stock Overview
A biomarker-based molecular diagnostics company, develops and commercializes molecular diagnostic products for the detection of cancer and various infectious diseases. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Genomictree Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₩15,150.00 |
| 52 Week High | ₩27,950.00 |
| 52 Week Low | ₩14,240.00 |
| Beta | -0.087 |
| 11 Month Change | -10.88% |
| 3 Month Change | -11.97% |
| 1 Year Change | -6.31% |
| 33 Year Change | 25.21% |
| 5 Year Change | -27.86% |
| Change since IPO | 236.67% |
Recent News & Updates
Shareholder Returns
| A228760 | KR Biotechs | KR Market | |
|---|---|---|---|
| 7D | -8.1% | -5.8% | -2.8% |
| 1Y | -6.3% | 28.2% | -3.4% |
Return vs Industry: A228760 underperformed the KR Biotechs industry which returned 30.2% over the past year.
Return vs Market: A228760 underperformed the KR Market which returned -4.4% over the past year.
Price Volatility
| A228760 volatility | |
|---|---|
| A228760 Average Weekly Movement | 7.8% |
| Biotechs Industry Average Movement | 8.3% |
| Market Average Movement | 5.7% |
| 10% most volatile stocks in KR Market | 11.5% |
| 10% least volatile stocks in KR Market | 2.7% |
Stable Share Price: A228760 has not had significant price volatility in the past 3 months compared to the KR market.
Volatility Over Time: A228760's weekly volatility (8%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2000 | 81 | Sung-Whan An | genomictree.com |
Genomictree Inc., a biomarker-based molecular diagnostics company, develops and commercializes molecular diagnostic products for the detection of cancer and various infectious diseases. The company offers EarlyTect C, a screening method for early diagnosis of colorectal cancer; EarlyTect L for detection of epigenetic markers associated with lung cancer in pulmonary nodule patients; and EarlyTect B for detection of genetic and epigenetic markers associated with bladder cancer in hematuria patients. It also provides AccuraDTect SARS-CoV-2 RT-qPCR kits, test providers, and nucleic acid transport medium products.
Genomictree Inc. Fundamentals Summary
| A228760 fundamental statistics | |
|---|---|
| Market cap | ₩363.33b |
| Earnings (TTM) | -₩9.56b |
| Revenue (TTM) | ₩2.04b |
178.2x
P/S Ratio-38.0x
P/E RatioIs A228760 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| A228760 income statement (TTM) | |
|---|---|
| Revenue | ₩2.04b |
| Cost of Revenue | ₩3.25b |
| Gross Profit | -₩1.21b |
| Other Expenses | ₩8.36b |
| Earnings | -₩9.56b |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -398.78 |
| Gross Margin | -59.27% |
| Net Profit Margin | -469.18% |
| Debt/Equity Ratio | 1.4% |
How did A228760 perform over the long term?
See historical performance and comparison